CN1166660C - Process for preparing N-methyl piperethanamine salt - Google Patents
Process for preparing N-methyl piperethanamine salt Download PDFInfo
- Publication number
- CN1166660C CN1166660C CNB02125317XA CN02125317A CN1166660C CN 1166660 C CN1166660 C CN 1166660C CN B02125317X A CNB02125317X A CN B02125317XA CN 02125317 A CN02125317 A CN 02125317A CN 1166660 C CN1166660 C CN 1166660C
- Authority
- CN
- China
- Prior art keywords
- methyl
- salt
- piperethanamine
- ethanol
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 128
- 239000007787 solid Substances 0.000 claims abstract description 69
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002253 acid Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 48
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 36
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 30
- -1 phenyl aldehyde Chemical class 0.000 claims description 30
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 27
- RRIRDPSOCUCGBV-UHFFFAOYSA-N methylenedioxyphenethylamine Chemical compound NCCC1=CC=C2OCOC2=C1 RRIRDPSOCUCGBV-UHFFFAOYSA-N 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 10
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 9
- 235000006408 oxalic acid Nutrition 0.000 claims description 9
- 235000002566 Capsicum Nutrition 0.000 claims description 7
- 239000006002 Pepper Substances 0.000 claims description 7
- 241000722363 Piper Species 0.000 claims description 7
- 235000016761 Piper aduncum Nutrition 0.000 claims description 7
- 235000017804 Piper guineense Nutrition 0.000 claims description 7
- 235000008184 Piper nigrum Nutrition 0.000 claims description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 abstract description 11
- 239000012454 non-polar solvent Substances 0.000 abstract description 4
- 239000002798 polar solvent Substances 0.000 abstract description 4
- 230000001476 alcoholic effect Effects 0.000 abstract description 3
- 238000010189 synthetic method Methods 0.000 abstract description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract 6
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 abstract 5
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 abstract 3
- 238000010992 reflux Methods 0.000 abstract 2
- ZILSBZLQGRBMOR-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine Chemical compound NCC1=CC=C2OCOC2=C1 ZILSBZLQGRBMOR-UHFFFAOYSA-N 0.000 abstract 1
- 239000007810 chemical reaction solvent Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- 235000019441 ethanol Nutrition 0.000 description 32
- 229960004756 ethanol Drugs 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 235000019253 formic acid Nutrition 0.000 description 14
- 229960000935 dehydrated alcohol Drugs 0.000 description 13
- 229960003299 ketamine Drugs 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- FXMXAFDOFYLVFW-UHFFFAOYSA-N 3-hydroxy-4-phenylbut-3-en-2-one Chemical compound CC(=O)C(O)=CC1=CC=CC=C1 FXMXAFDOFYLVFW-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229910021536 Zeolite Inorganic materials 0.000 description 4
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000010457 zeolite Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 229910014569 C—OOH Inorganic materials 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
Landscapes
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a preparation method for N-methyl piperathanamine salt, which has the steps that piperathanamine with a molar ratio of 0.4 to 1.2 reacts with benzaldehyde in a reflux mode in a polar solvent for 15 to 21 hours for acetalation; the solvent and the unreacted benzaldehyde are removed; the obtained N-methyl piperathanamine salt reacts with dimethyl sulfate in a nonpolar solvent with the temperature of 80 to 150 DEG C for 20 to 60 minutes, and becomes N methyl; the use quantity of the dimethyl sulfate is 0.8 to 1.5 times of the mole number of the piperonylamine; after the reaction solvent is removed, an alcohol solvent is added to the N-methyl piperathanamine salt and the dimethyl sulfate for a reflux reaction for 20 to 60 minutes; a small amount of water is then added to the N-methyl piperathanamine salt and the dimethyl sulfate; after the water, the N-methyl piperathanamine salt and the dimethyl sulfate are uniformly stirred, the solvent and the residual benzaldehyde are removed; the viscous oil type N-methyl piperathanamine salt is obtained; a basic saturated acid or anhydrous alcoholic solution is added to the viscous oil type object until the pH value becomes 1 to 4; N-methyl piperathanamine salt solid is gradually separated out. The method has the advantages of simple synthetic method, high yield and high product purity.
Description
Invention field
The present invention relates to a kind of preparation method of medicine intermediate, specifically, the present invention relates to the preparation method of N-methyl piperethanamine salt.
Background technology
Heart failure is the end stage eventually of cardiovascular diseases, the mortality ratio height.Myocardial infarction and reperfusion injury of cardiac muscle are to cause major reason in heart failure.Experimental study both domestic and external represents that calcium antagonist and free-radical scavengers have the treatment myocardial infarction and to the effect of anti reperfusion injury.Yet most of calcium antagonists suppress myocardial contraction, reduce heart function, and clinical application is restricted.Free-radical scavengers is to not directly influence of heart function, and its clinical effectiveness is not identified as yet.
Principle of reatment in heart failure is a cardiac stimulant, expands blood vessel and diuresis.Cardiac tonic improves heart output by strengthening myocardial contraction, keeps the blood supply of vitals such as heart and brain kidney; Expand blood vessel medicine and diuretic(s) by lowering cardiac load, the protection heart function.Yet, cardiotonic glycoside, catecholamine, the toxic reaction of phosphodiesterase inhibitor all types of cardiac tonics such as (PDEI) is bigger, because they are mainly by increasing intracellular calcium concentration, reach the effect that strengthens myocardial contraction, this just easily causes intracellular calcium overload, has arrhythogenic danger.Diuretic(s) Chang Zuowei drug of first choice is used for heart failure, still easily causes side effects such as electrolyte disturbance.The research in modern age represents that angiotensin converting enzyme inhibitor (ACEI) has the treatment congestive heart failure, and to resisting myocardial ischemia and the effect of reperfusion injury, its long-term effect waits to observe.
In a word, development has the effect characteristics, and toxic side effects is little, and chemical structure is novel, and the new drug of treatment cardiovascular diseases is clinical pressing for, and helps the pathophysiological mechanism of cardiovascular diseases is deepened understanding.
Summary of the invention
The object of the present invention is to provide the N-methyl piperethanamine salt, it is the intermediate of synthetic a kind of novel cardiovascular agent Xanthiphenyl ketamine and salt thereof.
Another object of the present invention is to provide the preparation method of N-methyl piperethanamine salt, described synthetic method is simple, yield is high, product purity is high, and product can be used to prepare the medicine Xanthiphenyl ketamine and the salt thereof for the treatment of cardiovascular diseases.
To achieve these goals, the technical solution used in the present invention is: the N-methyl piperethanamine salt, and its chemical structure is:
Wherein X is acid such as hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid.Title is respectively N-methyl piperethanamine salt hydrochlorate, N-methyl piperethanamine hydrobromate, N-methyl piperethanamine oxalate, N-methyl piperethanamine succinate, N-methyl piperethanamine maleate.
Preferred X is a hydrochloric acid, just N-methyl piperethanamine salt hydrochlorate.
The preparation method of N-methyl piperethanamine salt of the present invention is: the condensation in polar solvent of homopiperony lamine and phenyl aldehyde, N-benzal base pepper salt that obtains and methyl-sulfate reaction N methylate, product is handled with acid/ethanol solution, obtains the N-methyl piperethanamine salt.
The description that this method is more advanced-gone on foot is: the condensation in methyl alcohol, ethanol, propyl alcohol or tetrahydrofuran (THF) (THF) with homopiperony lamine and phenyl aldehyde, N-benzal base pepper salt that obtains and methyl-sulfate reaction, product is handled with hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid/anhydrous methanol, ethanol or propyl alcohol, obtains the N-methyl piperethanamine salt.
Specifically, the preparation method of N-methyl piperethanamine salt of the present invention comprises the steps:
1) homopiperony lamine and phenyl aldehyde back flow reaction acetalation in polar solvent (methyl alcohol, ethanol, propyl alcohol or tetrahydrofuran (THF)), the mol ratio of homopiperony lamine and phenyl aldehyde is 0.4-1.2, reaction times 15-21 hour, remove the phenyl aldehyde that desolvates and do not have reaction, the N-benzal base pepper salt that obtains;
2) N-benzal base pepper salt and methyl-sulfate 50-130 ℃ of reaction 20-60 minute in non-polar solvent (benzene,toluene,xylene or hexanaphthene), the consumption of methyl-sulfate be the homopiperony lamine mole number 0.8-1.5 doubly;
3) except that after desolvating, added alcoholic solvent (methyl alcohol, ethanol or propyl alcohol) back flow reaction 20-60 minute;
4) add 5-30ml water, the back that stirs is removed and is desolvated and residual phenyl aldehyde, obtains thickness oily matter N-methyl piperethanamine vitriol;
5) in thickness oily matter, add saturated substantially acid (hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid, preferred hydrochloric acid)/absolute alcohol (methyl alcohol, ethanol or propyl alcohol) solution to PH be 1-4, separate out N-methyl piperethanamine salt solid gradually.
Wherein, the polar solvent in the step 1) is methyl alcohol, ethanol, propyl alcohol one of them or tetrahydrofuran (THF), the consumption of solvent be homopiperony lamine and phenyl aldehyde gross weight 0.6-2 doubly.
Step 2) non-polar solvent in is one of them or a hexanaphthene of benzene,toluene,xylene, the consumption of non-polar solvent be homopiperony lamine and phenyl aldehyde gross weight 0.2-2 doubly.
Removing in the step 3) desolvated and can adopt the distillatory method, and described alcoholic solvent is methyl alcohol, ethanol or propyl alcohol, and consumption is homopiperony lamine and phenyl aldehyde gross weight 0.3-2 a times.
Alcohol in the step 5) is methyl alcohol, ethanol or propyl alcohol, and acid is a kind of of hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid etc.
Removing described in the above-mentioned steps desolvated, and can adopt the method for underpressure distillation.
The N-methyl piperethanamine salt solid that obtains can also be further with acetone or anhydrous diethyl ether washing, so that improve the purity of product N-methyl piperethanamine salt.
Above-mentioned preparation method's productive rate is 35-60wt%.
With the preferred N-methyl piperethanamine salt of the present invention hydrochlorate is example, and reaction process is expressed as follows:
The synthetic route of N-methyl piperethanamine salt of the present invention is reasonable in design, and synthesis technique is easy and simple to handle, and raw material is easy to get, stable reaction conditions, and the reaction yield height, good product purity can be used as the intermediate of synthetic hydrochloric acid Xanthiphenyl ketamine or other compounds.
Describe the present invention in detail below in conjunction with specific embodiment, described embodiment is used to describe the present invention rather than restriction the present invention.
Description of drawings:
Accompanying drawing 1 is the high pressure liquid chromatography figure of method synthetic Peperphentonamine hydrochloride of the present invention;
Accompanying drawing 2 is high pressure liquid chromatography figure of comparative example method synthetic Peperphentonamine hydrochloride of the present invention.
Embodiment
Experimental example 1
1.09mol homopiperony lamine (intermediate of Northeast Pharmaceutical Factory) and 1.96mol phenyl aldehyde are placed flask at the bottom of the 1000ml garden, mix, emit a large amount of heat, add 300ml dehydrated alcohol mixing, add zeolite, the heating of electricity consumption hot tap, back flow reaction 18 hours, concentrating under reduced pressure is removed ethanol, removes unreacted phenyl aldehyde with the oil pump concentrating under reduced pressure again, gets reddish-brown oily matter, behind the cool to room temperature, add 200ml toluene and 1.09mol methyl-sulfate again, outer temperature is maintained at about 120 ℃ of reactions 30 minutes, and room temperature leaves standstill cooling, treat the top toluene layer that inclines again after the layering, and then 75% ethanol of adding 300ml, back flow reaction is 30 minutes again, gets dark red-brown opaque liq.Adding distil water 10ml shakes up the back under whipped state, uses water pump to remove ethanol, toluene and water equal solvent under reduced pressure, remove phenyl aldehyde with the oil pump concentrating under reduced pressure again, get the opaque thickness oily matter of dark red-brown, in the extremely thick thing of gained, add saturated substantially HCl/ ethanol solution to PH=3, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous solid 89g, yield: 38%, mp:186～188 ℃ (dec.).R
f=0.23 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis and theoretical value are approaching.
Experimental example 2
0.8mol homopiperony lamine (intermediate of Northeast Pharmaceutical Factory) and 1.0mol phenyl aldehyde are placed flask at the bottom of the 1000ml garden, mix, emit a large amount of heat, add 200ml anhydrous methanol mixing, add zeolite, the heating of electricity consumption hot tap, back flow reaction 21 hours, concentrating under reduced pressure is removed methyl alcohol, removes unreacted phenyl aldehyde with the oil pump concentrating under reduced pressure again, gets reddish-brown oily matter, behind the cool to room temperature, add 100ml benzene and 1.0mol methyl-sulfate again, outer temperature is maintained at about 80 ℃ of reactions 60 minutes, and room temperature leaves standstill cooling, treat the benzene layer that inclines top again after the layering, and then 75% ethanol of adding 200ml, back flow reaction is 40 minutes again, gets dark red-brown opaque liq.Adding distil water 15ml shakes up the back under whipped state, uses water pump to remove ethanol, toluene and water equal solvent under reduced pressure, remove phenyl aldehyde with the oil pump concentrating under reduced pressure again, get the opaque thickness oily matter of dark red-brown, in the extremely thick thing of gained, add saturated substantially HCl/ ethanol solution to PH=4, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous solid, yield: 35%, mp:186～188 ℃ (dec.).R
f=0.23 (developping agent: CH
2Cl
2: CH
30H: HCOOH=10: 0.8: 0.08), ultimate analysis and theoretical value are approaching.
Experimental example 3
1.2mol homopiperony lamine (intermediate of Northeast Pharmaceutical Factory) and 1.5mol phenyl aldehyde are placed flask at the bottom of the 1000ml garden, mix, emit a large amount of heat, add the anhydrous THF mixing of 400ml, add zeolite, the heating of electricity consumption hot tap, back flow reaction 15 hours, the water pump concentrating under reduced pressure is removed THF, removes unreacted phenyl aldehyde with the oil pump concentrating under reduced pressure again, gets reddish-brown oily matter, behind the cool to room temperature, add 200ml toluene and 1.4mol methyl-sulfate again, outer temperature is maintained at about 130 ℃ of reactions 40 minutes, and room temperature leaves standstill cooling, treat the top toluene layer that inclines again after the layering, and then 75% ethanol of adding 400ml, back flow reaction is 50 minutes again, gets dark red-brown opaque liq.Adding distil water 20ml shakes up the back under whipped state, uses water pump to remove ethanol, toluene and water equal solvent under reduced pressure, remove phenyl aldehyde with the oil pump concentrating under reduced pressure again, get the opaque thickness oily matter of dark red-brown, in the extremely thick thing of gained, add saturated substantially HCl/ absolute methanol solution to PH=1-3, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous solid, yield: 40%, mp:186～188 ℃ (dec.).R
f=0.23 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis and theoretical value are approaching.
Experimental example 4
0.4mol homopiperony lamine (intermediate of Northeast Pharmaceutical Factory) and 0.8mol phenyl aldehyde are placed flask at the bottom of the 1000ml garden, mix, emit a large amount of heat, add 150ml dehydrated alcohol mixing, add zeolite, the heating of electricity consumption hot tap, back flow reaction 20 hours, the water pump concentrating under reduced pressure is removed ethanol, removes unreacted phenyl aldehyde with the oil pump concentrating under reduced pressure again, gets reddish-brown oily matter, behind the cool to room temperature, add 45ml hexanaphthene and 0.6mol methyl-sulfate again, outer temperature is maintained at about 100 ℃ of reactions 20 minutes, and room temperature leaves standstill cooling, treat the top toluene layer that inclines again after the layering, and then 75% ethanol of adding 200ml, back flow reaction is 50 minutes again, gets dark red-brown opaque liq.Adding distil water 12ml shakes up the back under whipped state, uses water pump to remove ethanol, hexanaphthene and water equal solvent under reduced pressure, remove phenyl aldehyde with the oil pump concentrating under reduced pressure again, get the opaque thickness oily matter of dark red-brown, in the extremely thick thing of gained, add saturated substantially HCl/ absolute methanol solution to PH=3.5, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous solid, yield: 380%, mp:186～188 ℃ (dec.).R
f=0.23 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08).
Embodiment 5
Method with reference to embodiment 1, difference is to add saturated substantially HBr/ ethanol solution to Ph=2 in the thickness oily matter that finally obtains, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous N-methyl piperethanamine hydrobromate solid.
Embodiment 6
Method with reference to embodiment 1, difference is to add saturated substantially oxalic acid/ethanol solution to Ph=2 in the thickness oily matter that finally obtains, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous N-methyl piperethanamine oxalate solid.
Embodiment 7
Method with reference to embodiment 1, difference is to add saturated substantially succsinic acid/ethanol solution to Ph=3 in the thickness oily matter that finally obtains, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous N-methyl piperethanamine succinate solid.
Embodiment 8
Method with reference to embodiment 1, difference is to add saturated substantially toxilic acid/ethanol solution to Ph=4 in the thickness oily matter that finally obtains, separate out a large amount of solids gradually, filter, solid is washed repeatedly, is washed with anhydrous diethyl ether with acetone, gets subalbous N-methyl piperethanamine maleate solid.
Embodiment 9
Obtain the hydroxyl benzylideneacetone through the Claisen-Schmidt condensation reaction with acetone under alkaline condition by p-Hydroxybenzaldehyde.
21.5g (0.1mol) N-methyl piperethanamine salt hydrochlorate and 30g (1mol) Paraformaldehyde 96 are placed the 500ml round-bottomed bottle, add 240ml dehydrated alcohol and 2ml concentrated hydrochloric acid, make solution be acid, outer temperature remains in the 90-100 ℃ of oil bath and heats, after being stirred to solid and all dissolving, reheat stirred about 30 minutes, cold slightly, add hydroxyl benzylideneacetone 16.2g ((0.1mol), about 8.0 hours of backflow stirring reaction, slowly separate out solid in the reaction process, in reaction flask, all solidify.Detect R with TLC
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), reaction is complete substantially.Filter, solid is washed repeatedly with the refrigerative dehydrated alcohol, drying.Get faint yellow solid 27.3g.This solid is with 95% ethanol heated and stirred, the very fast whole dissolvings of solid are lurid settled solution, use the 3g activated carbon decolorizing again, get lurid settled solution, put and slowly separate out the white powder solid after cold, and then put the refrigerator cooling, and filter, get subalbous Peperphentonamine hydrochloride pulverulent solids, wash with dehydrated alcohol, vacuum-drying, heavy 22g, yield: 69%.mp：168～170℃。R
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis is near theoretical value, and high pressure liquid chromatography detects, and purity is about 99.3%, referring to Fig. 1.Results of elemental analyses:
| Element | C(％) | H(％) | N(％) | Cl(％) |
| Calculated value | 64.69 | 6.16 | 3.59 | 9.114 |
| Measured value | 64.57 | 6.19 | 3.69 | 9.01 |
| 64.78 | 6.04 | 3.44 | 9.14 |
Mass spectrum: m/s 218,135.
Infrared absorption spectrum (IR) detected result sees Table 1:
Table 1
| Absorption peak (cm -1) | Oscillatory type | Group | Absorption peak strength |
| 3080 2960 | vas C-H | Phenyl ring CH 2 | S M |
| 1684 | vas C＝O | The unsaturated C=O of α β | M |
| 1655 1593 1514 | vas C＝C | Phenyl ring connects the phenyl ring of carbonyl | Weak S M |
| 1284 1242 1192 1111 1032 970 924 | vas C-OH | The phenolic hydroxyl group phenyl ring | M M |
| 1192，1169 | vas c-o-c-o-c | On the phenyl ring | M |
| 823 | vas C-H | Phenyl ring (1,4-two replaces) | M |
Proton nmr spectra (DMSO-d
6, TMS) the results are shown in Table 2
Structural formula:
Table 2 Peperphentonamine hydrochloride
1H-NMR composes resolution table
| Sequence number | Chemical shift (δ) | The peak type | Proton number | Corresponding proton |
| 21 | 2.796 | s | 3H | N-CH 3 |
| 13 | 2.910 | br.t | 2H | -CH 2 |
| 11 | 3.281 | br.m | 2H | -CH 2 |
| 10 | 3.320 | br.t | 2H | -CH 2 |
| 12 | 3.421 | br.m | 2H | -CH 2 |
| 20 | 5.896 | s | 2H | -OCH 2O- |
| 8 | 6.659 | d，J＝16.5Hz | 1H | -C-H |
| 19 | 6.746 | dd，J＝8.0Hz J＝1.50Hz | 1H | -C-H |
| 18 | 6.80 | d，J＝8.0Hz | 1H | -C-H |
| 2，6 | 6.823 | A 2B 2，d，J＝9.0Hz | 2H | -C-H |
| 15 | 6.861 | d，J＝1.50Hz | 1H | -C-H |
| 3，5 | 7.533 | A 2B 2，d，J＝9.0Hz | 2H | -C-H |
| 7 | 7.582 | d，J＝16.5Hz | 1H | -C-H |
| 1 | 10.195 | Br.s D 2The O exchange | 1H | -C-OOH |
6.3.4 carbon-13 nmr spectra and carbon, the relevant spectrum of hydrogenation displacement study see Table 3:
Table 3. Peperphentonamine hydrochloride
13C-NMR composes resolution table
| The carbon sequence number | Chemical shift (δ) | The carbon sequence number | Chemical shift (δ) |
| C-1 | 160.260 | C-13 | 29.109 |
| C-2，6 | 115.939 | C-14 | 130.630 |
| C-4 | 125.020 | C-15 | 109.129 |
| C-3，5 | 130.555 | C-16 | 146.009 |
| C-7 | 143.714 | C-17 | 147.361 |
| C-8 | 122.551 | C-18 | 108.318 |
| C-9 | 196.187 | C-19 | 121.805 |
| C-10 | 33.886 | C-20 | 100.839 |
| C-11 | 55.959 | C-21 | 39.384 |
| C-12 | 50.236 |
Embodiment 10
17.2g (0.08mol) N-methyl piperethanamine salt hydrochlorate and 24g (0.8mol) Paraformaldehyde 96 are placed the 500ml round-bottomed bottle, add 200ml dehydrated alcohol and 1.5ml concentrated hydrochloric acid, make PH be about 3-4,100 ℃ of oil bath temperatures are after heated and stirred to solid all dissolves, reheat, stirring about 20 minutes, cold slightly, add hydroxyl benzylideneacetone 16.2g ((0.1mol), about 6.0 hours of backflow stirring reaction, slowly separate out solid in the reaction process, in reaction flask, all solidify.Detect R with TLC
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), reaction is complete substantially.Filter, solid is washed repeatedly with dehydrated alcohol, drying.Get faint yellow solid.This solid 95% ethyl alcohol recrystallization obtains pale yellow powder shape solid, cools off then, filters, and uses absolute ethanol washing, gets subalbous Peperphentonamine hydrochloride pulverulent solids, vacuum-drying, heavy 15.58g, yield: 60.1%.mp：167～169℃。R
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis is near theoretical value, and high pressure liquid chromatography detects, and purity is about 98.6%.
Embodiment 11
25.8g (0.12mol) N-methyl piperethanamine salt hydrochlorate and 36g (1.2mol) Paraformaldehyde 96 are placed the 500ml round-bottomed bottle, add 320ml dehydrated alcohol and 2.0mol concentrated hydrochloric acid, make PH be about 4,90 ℃ of oil bath temperatures are after heated and stirred to solid all dissolves, reheat, stirring 10 minutes, cold slightly, add to hydroxyl benzylideneacetone 16.2g (0.1mol) about 9.5 hours of backflow stirring reaction, slowly separate out solid in the reaction process, in reaction flask, all solidify.Detect R with TLC
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), reaction is complete substantially.Filter, all dehydrated alcohols of solid are washed repeatedly, are dried, and get faint yellow solid.This solid ethyl alcohol recrystallization obtains faint yellow Peperphentonamine hydrochloride pulverulent solids, cools off then, filters, and uses absolute ethanol washing, gets subalbous pulverulent solids, vacuum-drying, yield: 62%.mp：167～169℃。R
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis is near theoretical value, and high pressure liquid chromatography detects, and purity is about 98.8%.
Embodiment 12
43.0g (0.2mol) N-methyl piperethanamine salt hydrochlorate and 45g (1.5mol) Paraformaldehyde 96 are placed the 1000ml round-bottomed bottle, add 400ml dehydrated alcohol and concentrated hydrochloric acid, make PH be about 3-4,95 ℃ of oil bath temperatures are after heated and stirred to solid all dissolves, reheat, stirring 25 minutes, cold slightly, add hydroxyl benzylideneacetone 24.3g ((0.15mol), about 7 hours of backflow stirring reaction, slowly separate out solid in the reaction process, in reaction flask, all solidify.Detect R with TLC
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), reaction is complete substantially.Filter, solid with dehydrated alcohol wash repeatedly, drying, faint yellow solid.This solid ethyl alcohol recrystallization obtains pale yellow powder shape solid, cools off then, filters, and uses absolute ethanol washing, gets subalbous Peperphentonamine hydrochloride pulverulent solids, vacuum-drying, yield: 56.4%.mp：167～169℃。R
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis is near theoretical value, and high pressure liquid chromatography detects, and purity is about 98.5%.
Embodiment 13
32.25g (0.15mol) N-methyl piperethanamine salt hydrochlorate and 45g (1.5mol) Paraformaldehyde 96 are placed the 1000ml round-bottomed bottle, add 350ml dehydrated alcohol and concentrated hydrochloric acid, adjust PH and be about 3-5,100 ℃ of oil bath temperatures, after heated and stirred to solid all dissolves, add hydroxyl benzylideneacetone 16.2g ((0.1mol), about 7.5 hours of backflow stirring reaction, slowly separate out solid in the reaction process, in reaction flask, all solidify.Detect R with TLC
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), reaction is complete substantially.Filter out solvent, solid is washed repeatedly with dehydrated alcohol, drying.Get faint yellow solid.This solid is with 95% ethanol heated and stirred, the very fast whole dissolvings of solid are lurid settled solution, use the 3g activated carbon decolorizing again, lurid settled solution, put and slowly separate out the white powder solid after cold, cool off then, filter, get subalbous pulverulent solids, wash vacuum-drying with dehydrated alcohol, obtain Peperphentonamine hydrochloride, yield: 58.9%.mp：168～170℃。R
f=0.38 (developping agent: CH
2Cl
2: CH
3OH: HCOOH=10: 0.8: 0.08), ultimate analysis is near theoretical value, and high pressure liquid chromatography detects purity 99.5%
Embodiment 14
1.5g Peperphentonamine hydrochloride, sodium hydrogen carbonate solution (pH=9) that 200ml is saturated and 80 ethyl acetate are mixed, stirring at room three hours, solid dissolve gradually settled solution, the intact R of TLC reaction
f=0.49 (developping agent: CH
2Cl
2: CH
3OH=10: 0.8), tell the upper strata ethyl acetate solution, wash neutrality with water, use anhydrous sodium sulfate drying, filter, get subalbous pulverulent solids, wash with anhydrous diethyl ether, vacuum-drying gets Xanthiphenyl ketamine pulverulent solids 1.3g, yield: 95.6%.mp：142～143℃。Results of elemental analyses and theoretical value are approaching.
Embodiment 15
It according to mol ratio 1: 1.2 ratio, Xanthiphenyl ketamine is reacted salify with acid such as Hydrogen bromide, oxalic acid, succsinic acid or toxilic acids respectively under the room temperature in ethyl acetate, the TLC monitoring reaction, to the Xanthiphenyl ketamine disappearance, wash neutrality with water, use anhydrous sodium sulfate drying, filter, get subalbous pulverulent solids, wash vacuum-drying with anhydrous diethyl ether.Obtain Xanthiphenyl ketamine hydrobromate, Xanthiphenyl ketamine oxalate, Xanthiphenyl ketamine succinate, Xanthiphenyl ketamine maleate salt respectively, results of elemental analyses and theoretical value are approaching.
Claims (9)
1, N-methyl piperethanamine salt, its chemical structure is:
Wherein X is hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid.
2, N-methyl piperethanamine salt according to claim 1 is characterized in that X is a hydrochloric acid.
3, the preparation method of the described N-methyl piperethanamine salt of claim 1 is characterized in that; The condensation in methyl alcohol, ethanol, propyl alcohol or tetrahydrofuran (THF) with homopiperony lamine and phenyl aldehyde, N-benzal base pepper salt that obtains and methyl-sulfate reaction, product is handled with hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid/anhydrous methanol, ethanol or propyl alcohol, obtains the N-methyl piperethanamine salt.
4, the preparation method of N-methyl piperethanamine salt according to claim 3 comprises the steps:
1) homopiperony lamine and phenyl aldehyde back flow reaction in methyl alcohol, ethanol, propyl alcohol or tetrahydrofuran (THF), the mol ratio of homopiperony lamine and phenyl aldehyde is 0.4-1.2, reaction times 15-21 hour, remove the phenyl aldehyde that desolvates and do not have reaction, obtain N-benzal base pepper salt;
2) N-benzal base pepper salt and methyl-sulfate are in benzene,toluene,xylene or hexanaphthene, and 50-130 ℃ was reacted 20-60 minute, and the consumption of methyl-sulfate is 0.8-1.5 a times of homopiperony lamine mole number;
3) except that after desolvating, add methyl alcohol, ethanol or propyl alcohol, back flow reaction 20-60 minute;
4) add 5-30ml water, the back that stirs is removed and is desolvated and residual phenyl aldehyde, obtains thickness oily matter N-methyl piperethanamine vitriol;
5) in thickness oily matter, add saturated substantially hydrochloric acid, Hydrogen bromide, oxalic acid, succsinic acid or toxilic acid/anhydrous methanol, ethanol or propanol solution to PH be 1-4, separate out N-methyl piperethanamine salt solid gradually.
5, the preparation method of N-methyl piperethanamine salt according to claim 4, the consumption that it is characterized in that methyl alcohol, ethanol, propyl alcohol or tetrahydrofuran solvent in the step 1) is homopiperony lamine and phenyl aldehyde gross weight 0.6-2 a times.
6, the preparation method of N-methyl piperethanamine salt according to claim 4 is characterized in that step 2) in benzene,toluene,xylene or the consumption of hexanaphthene be homopiperony lamine and phenyl aldehyde gross weight 0.2-2 doubly.
7, the preparation method of N-methyl piperethanamine salt according to claim 4, it is characterized in that desolvating removing in the step 3), to adopt distillatory method, the consumption of described methyl alcohol, ethanol or propyl alcohol be homopiperony lamine and phenyl aldehyde gross weight 0.3-2 times.
8, the preparation method of N-methyl piperethanamine salt according to claim 4 is characterized in that the acid in the step 5) is hydrochloric acid.
9, the preparation method of N-methyl piperethanamine salt according to claim 4 is characterized in that removing desolvating and adopts the method for underpressure distillation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02125317XA CN1166660C (en) | 2002-07-24 | 2002-07-24 | Process for preparing N-methyl piperethanamine salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02125317XA CN1166660C (en) | 2002-07-24 | 2002-07-24 | Process for preparing N-methyl piperethanamine salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1396160A CN1396160A (en) | 2003-02-12 |
| CN1166660C true CN1166660C (en) | 2004-09-15 |
Family
ID=4745522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02125317XA Expired - Lifetime CN1166660C (en) | 2002-07-24 | 2002-07-24 | Process for preparing N-methyl piperethanamine salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1166660C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8513301B2 (en) | 2007-01-31 | 2013-08-20 | Guangzhou Zhongwei Biotechnology Ltd. | Kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof |
| CN102697766B (en) * | 2012-05-18 | 2013-08-21 | 广州军区广州总医院 | Application of N-methyl piperonylethylamine and salts of N-methyl piperonylethylamine in preparation of drugs for preventing and/or treating encephalopathy |
| CN102936241A (en) * | 2012-11-14 | 2013-02-20 | 广西师范大学 | Homopiperony lamine pyridine-2-formaldehyde and synthetic method and application thereof |
| CN106892892B (en) * | 2017-01-17 | 2019-08-13 | 内蒙古医科大学 | Fragrant oxygen acid derivative containing piperonyl cyclonene and preparation method thereof |
| CN114113409A (en) * | 2021-12-06 | 2022-03-01 | 苏州健雄职业技术学院 | High performance liquid chromatography detection method for berberine intermediate |
-
2002
- 2002-07-24 CN CNB02125317XA patent/CN1166660C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1396160A (en) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101412670B (en) | Method for synthesizing loxoprofen sodium | |
| CN113233975B (en) | Preparation method of bevacizidine acid | |
| CN1166660C (en) | Process for preparing N-methyl piperethanamine salt | |
| CN108707221A (en) | Conjugated polymer and the preparation method and application thereof of the one kind based on the high two-photon absorption of naphtho- indenes fluorenes | |
| CN113735847B (en) | Synthetic preparation method of berberine hydrochloride | |
| CN1164585C (en) | Xanthiphenyl ketamine or its salt and its preparing process | |
| CN103183673B (en) | The synthetic method of (S, S)-2,8-diazabicyclo [4,3,0] nonane | |
| CN113831318A (en) | Synthetic method of piperonylethylamine | |
| CN110627772A (en) | Pinene-fused chiral terpyridine bidentate compound and preparation method thereof | |
| CN101665418B (en) | Methods for preparing E-3,5-dimethoxy-4'-oxhydryl diphenylethene and derivative thereof | |
| CN112174823B (en) | Intermediate for synthesizing 2, 2-dimethyl-3-oxetanone and preparation method and application thereof | |
| CN109232544B (en) | Preparation method of prucalopride | |
| CN103864747B (en) | The total synthesis method of mangostin | |
| CN102344361B (en) | High selectivity synthesis method of benzoyl formic acid | |
| CN110452199B (en) | Preparation method of feloxicib | |
| JPH01186844A (en) | Production of 3-(4'-bromobiphenyl)-3-hydroxyl- 4-phenylbutyric ester | |
| CN110724276B (en) | Preparation method of acid-alkali difunctional MOFs material and method for synthesizing 3, 4-dimethylfurazan by using acid-alkali difunctional MOFs material as catalyst | |
| CN112430205B (en) | Preparation method of arylpyrrole compound | |
| CN112794837B (en) | Synthesis method of heterochroman compound | |
| CN111499524B (en) | Method for preparing amino alcohol compound by using halogenated intermediate | |
| CN112521364B (en) | Galanthamine intermediate compound V | |
| WO2005016937A1 (en) | A SYNTHETIC METHOD FOR 6-CHLORO-4-HYDROXY-2-METHYL-2H-THIENO (2,3-e)-1,2-THIAZINE1, 1-DIOXIDE-3-CARBOXYLATE | |
| TW200306304A (en) | Process for the preparation of bicyclic diketone salts | |
| CN114380681A (en) | Synthetic method of 2- (bromomethyl) -2-butyl hexanoic acid | |
| US8552195B2 (en) | Method for making donepezil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHONGWEI BIOTECHNOLOGY CO LTD, GUANGZHOU CITY; BE Free format text: FORMER OWNER: ZHONGWEI BIOTECHNOLOGY CO LTD, GUANGZHOU CITY Effective date: 20081107 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081107 Address after: No. 133, Tianhe Sports West Road, Guangzhou, Guangdong Province, China: 510620 Co-patentee after: BEIJING SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. Co-patentee after: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Address before: No. 133, Tianhe Sports West Road, Guangzhou, Guangdong Province, China: 510620 Patentee before: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BEIJING SIHUAN PHARMACEUTICAL CO., LTD. HAINAN SIHUAN PHARMACEUTICAL CO.,LTD HAINAN SIHUAN RESEARCH INSTITUTE OF CARDIO-CEREBRAL VASCULAR MEDICINE CO., LTD. SHENZHEN SIHUAN PHARMACEUTICAL CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510620 GUANGZHOU, GUANGDONG PROVINCE TO: 510663 GUANGZHOU, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110907 Address after: 510663 Guangzhou City Luogang District of Guangzhou high tech Industrial Development Zone, Science City E413 skim Springs Road No. 3 Guangzhou international business incubator District E room Patentee after: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. Address before: 510620 No. 133 Sports West Road, Tianhe, Guangdong, Guangzhou Co-patentee before: BEIJING SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee before: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. Co-patentee before: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Co-patentee before: Hainan Sihuan Cardiovascular Drug Research Institute Co.,Ltd. Co-patentee before: Shenzhen Sihuan Pharmaceutical Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGWEI BIOTECHNOLOGY CO LTD, GUANGZHOU CITY Effective date: 20140121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510633 GUANGZHOU, GUANGDONG PROVINCE TO: 214000 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140121 Address after: 214000 No. 12 Changjiang Road, New District, Jiangsu, Wuxi Patentee after: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL Co.,Ltd. Address before: 510633 Guangdong city of Guangzhou province Luogang District of Guangzhou high tech Industrial Development Zone, Science City E413 skim Springs Road No. 3 Guangzhou international business incubator District E room Patentee before: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 214028 Changjiang South Road, new Wu District, Wuxi, Jiangsu Province, No. 12 Patentee after: Wuxi Jiyu Shanhe Pharmaceutical Co.,Ltd. Address before: No.12, Changjiang Road, New District, Wuxi, Jiangsu Province Patentee before: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040915 |